Schott establishes stand-alone company for its pharma business

1 August 2022

German glass company Schott has established a stand-alone company for its pharma business to advance its growth strategy.

Following the spin-out, Schott Pharma will seek to develop new opportunities with a portfolio that currently ranges from high-quality vials to glass and polymer syringes, to cartridges and ampoules.

"This step enables us to explore new financing options, including a possible IPO for Schott Pharma"The multinational group’s pharma division has grown faster than the market in recent years, producing around 13 billion products yearly to serve modern drug categories such as mRNA-based drugs and biopharmaceuticals. Currently, Schott Pharma has more than 1,700 customers including the top 30 leading pharma manufacturers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK